The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
作者信息
Marchesi Francesco, Pimpinelli Fulvia, Sperandio Eleonora, Papa Elena, Falcucci Paolo, Pontone Martina, di Martino Simona, de Latouliere Luisa, Orlandi Giulia, Morrone Aldo, Ciliberto Gennaro, Mengarelli Andrea
机构信息
Haematology Unit, Department of Research and Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Microbiology and Virology Unit, Dermatological Clinical and Research Department, IRCCS San Gallicano Institute, Rome, Italy.
出版信息
Br J Haematol. 2022 Jan;196(2):362-367. doi: 10.1111/bjh.17821. Epub 2021 Sep 6.
Abstract
摘要
相似文献
1
The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.接种BNT162b2疫苗后不同血液系统癌症中抗SARS-CoV-2抗体的12周动力学
Br J Haematol. 2022 Jan;196(2):362-367. doi: 10.1111/bjh.17821. Epub 2021 Sep 6.
2
Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.与完全接种 BNT162b2 疫苗的患者相比，感染 COVID-19 的骨髓瘤患者具有更高的抗体反应。
Br J Haematol. 2022 Jan;196(2):356-359. doi: 10.1111/bjh.17841. Epub 2021 Sep 16.
3
Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.韩国医护人员接种第二剂 BNT162b2 mRNA 疫苗 6 个月后仍保持对 SARS-CoV-2 的抗体应答。
Front Immunol. 2022 Jan 31;13:827306. doi: 10.3389/fimmu.2022.827306. eCollection 2022.
4
Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.接受CAR T细胞疗法治疗的患者接种一剂和/或两剂BNT162b2抗SARS-CoV-2 mRNA疫苗后的安全性和抗体反应。
Br J Haematol. 2022 Jan;196(2):360-362. doi: 10.1111/bjh.17818. Epub 2021 Sep 2.
5
The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.mRNA-1273 新冠病毒疫苗在血液透析患者中的安全性和免疫原性。
Front Immunol. 2021 Jun 16;12:704773. doi: 10.3389/fimmu.2021.704773. eCollection 2021.
6
Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.第三剂 BNT162b2 疫苗可诱导先前无反应的老年人群产生针对 SARS-CoV-2 的强大细胞和体液免疫。
Nat Microbiol. 2022 Feb;7(2):195-199. doi: 10.1038/s41564-021-01046-z. Epub 2022 Jan 10.
7
Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.BNT162b2 mRNA新冠疫苗接种后糖尿病和非糖尿病个体均产生强劲抗体水平。
Front Immunol. 2021 Nov 24;12:752233. doi: 10.3389/fimmu.2021.752233. eCollection 2021.
8
Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.多发性骨髓瘤和华氏巨球蛋白血症无症状前驱期患者对SARS-CoV-2疫苗的反应减弱。
Cancer Cell. 2022 Jan 10;40(1):6-8. doi: 10.1016/j.ccell.2021.12.003. Epub 2021 Dec 9.
9
Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.血液学和肿瘤学患者中BNT162b2 mRNA新冠疫苗的血清学SARS-CoV-2抗体反应、潜在预测标志物及安全性
Br J Haematol. 2021 Nov;195(4):523-531. doi: 10.1111/bjh.17743. Epub 2021 Aug 3.
10
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.造血干细胞移植患者接种BNT162b2抗SARS-CoV-2 mRNA疫苗后的血清学反应。
Br J Haematol. 2022 Feb;196(4):928-931. doi: 10.1111/bjh.17873. Epub 2021 Oct 18.
引用本文的文献
1
Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis.与健康对照相比，新冠病毒疫苗在血液系统恶性肿瘤患者中的疗效：一项系统评价和荟萃分析
JMA J. 2024 Apr 15;7(2):153-171. doi: 10.31662/jmaj.2023-0171. Epub 2024 Apr 1.
2
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.血液系统恶性肿瘤患者和老年人群对三剂抗 SARS-CoV-2 BNT162b2 疫苗的体液和细胞反应动力学。
Front Immunol. 2024 Jan 26;14:1221587. doi: 10.3389/fimmu.2023.1221587. eCollection 2023.
3
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.成年癌症患者对新冠病毒疫苗全程接种和加强针的体液免疫反应受损，尤其是正在接受积极治疗的血液系统癌症患者：一项系统评价和荟萃分析。
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
4
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
5
Effectiveness and Safety of COVID-19 Vaccination in Patients with Malignant Disease.新冠病毒疫苗在恶性疾病患者中的有效性和安全性
Vaccines (Basel). 2023 Feb 20;11(2):486. doi: 10.3390/vaccines11020486.
6
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.免疫原性和与血液恶性肿瘤患者在接种 SARS-CoV-2 疫苗和加强针后免疫反应受损相关的风险：一项更新的荟萃分析。
Blood Cancer J. 2022 Dec 23;12(12):173. doi: 10.1038/s41408-022-00776-5.
7
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.一项系统评价和荟萃分析：成人血液恶性肿瘤患者对 SARS-CoV-2 疫苗首剂和第 2 剂的免疫应答。
Int Immunopharmacol. 2022 Sep;110:109046. doi: 10.1016/j.intimp.2022.109046. Epub 2022 Jul 12.
8
Development of Approaches and Metrics to Measure the Impact and Improve the Clinical Outcomes of Patients With Frailty in the Era of COVID-19. The COMETA Italian Protocol.COVID-19时代测量衰弱患者影响并改善其临床结局的方法与指标的制定。COMETA意大利方案。
Front Oncol. 2022 Jun 2;12:828660. doi: 10.3389/fonc.2022.828660. eCollection 2022.
9
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.癌症患者的 COVID-19 疫苗：免疫原性、疗效和安全性。
Nat Rev Clin Oncol. 2022 Jun;19(6):385-401. doi: 10.1038/s41571-022-00610-8. Epub 2022 Mar 11.
10
Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.血液恶性肿瘤患者治疗对 SARS-CoV-2 疫苗接种后血清转化率的影响。
Oncologist. 2022 Apr 5;27(4):e357-e361. doi: 10.1093/oncolo/oyac032.
本文引用的文献
1
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.与真性红细胞增多症和原发性血小板增多症患者相比，骨髓纤维化患者对BNT162b2疫苗的反应较低。
J Hematol Oncol. 2021 Jul 29;14(1):119. doi: 10.1186/s13045-021-01130-1.
2
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.多发性骨髓瘤患者对两剂新冠病毒RNA疫苗的严重急性呼吸综合征冠状病毒2刺突抗体反应高度可变。
Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.
3
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.接受B细胞定向疗法的淋巴瘤患者对新冠疫苗接种的体液免疫反应受损。
Blood. 2021 Sep 2;138(9):811-814. doi: 10.1182/blood.2021012443.
4
Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses.SARS-CoV-2 疫苗抗体反应的初次应答、回忆应答和衰减动力学。
ACS Nano. 2021 Jul 27;15(7):11180-11191. doi: 10.1021/acsnano.1c03972. Epub 2021 Jun 23.
5
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.一剂 BNT162b2 mRNA 疫苗可诱导慢性髓性白血病患者产生针对严重急性呼吸综合征冠状病毒-2（SARS-CoV-2）的中和抗体和多功能 T 细胞反应。
Br J Haematol. 2021 Sep;194(6):999-1006. doi: 10.1111/bjh.17568. Epub 2021 Jun 3.
6
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.单剂量BNT162b2 mRNA新冠疫苗可在骨髓增殖性肿瘤患者中诱导出高频率的中和抗体及多功能T细胞反应。
Leukemia. 2021 Dec;35(12):3573-3577. doi: 10.1038/s41375-021-01300-7. Epub 2021 May 22.
7
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.第五周抗 SARS-CoV-2 BNT162b2 疫苗在接受积极治疗的多发性骨髓瘤和骨髓增生性恶性肿瘤患者中的免疫原性和安全性：来自单一机构的初步数据。
J Hematol Oncol. 2021 May 17;14(1):81. doi: 10.1186/s13045-021-01090-6.
8
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.2019冠状病毒病疫苗对慢性淋巴细胞白血病患者的疗效
Leukemia. 2021 Sep;35(9):2703-2705. doi: 10.1038/s41375-021-01270-w. Epub 2021 May 13.
9
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.癌症患者接种一剂与两剂新冠疫苗BNT162b2的安全性和免疫原性：一项前瞻性观察研究的中期分析
Lancet Oncol. 2021 Jun;22(6):765-778. doi: 10.1016/S1470-2045(21)00213-8. Epub 2021 Apr 27.
10
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.多发性骨髓瘤患者对严重急性呼吸综合征冠状病毒2首次疫苗接种的反应。
Lancet Haematol. 2021 Jun;8(6):e389-e392. doi: 10.1016/S2352-3026(21)00110-1. Epub 2021 Apr 19.
Zotero 插件